stockrowRepligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
Follow RGEN
Alert me
Repligen Corporation (RGEN) Revenue
Repligen Corporation's revenue for fiscal 2025 was $738.3M, up 16.4% from $634.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $805.6M. Over the past ten years it has ranged from $83.5M (fiscal 2015) to $801.5M (fiscal 2022); the current reading is higher than 91% of that period. Repligen Corporation ranks 23rd of 47 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $738.3M | 16.36% |
| FY2024 | $634.4M | 0.33% |
| FY2023 | $632.4M | (21.11%) |
| FY2022 | $801.5M | 19.54% |
| FY2021 | $670.5M | 83.08% |
| FY2020 | $366.3M | 35.53% |
| FY2019 | $270.2M | 39.28% |
| FY2018 | $194.0M | 37.38% |
| FY2017 | $141.2M | 35.10% |
| FY2016 | $104.5M | 25.14% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $209.3M | 2.54% |
| Jun 2026 | $204.1M | 5.08% |
| Mar 2026 | $194.3M | (1.85%) |
| Dec 2025 | $197.9M | 4.82% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BAX Baxter International Inc. compare | $11.6B |
| SOLV Solventum Corporation compare | $8.2B |
| AVTR Avantor, Inc. compare | $6.6B |
| BLCO Bausch + Lomb Corporation compare | $5.4B |
| COO The Cooper Companies, Inc. compare | $4.2B |
| ALGN Align Technology, Inc. compare | $4.2B |
| ATR AptarGroup, Inc. compare | $4.0B |
| TFX Teleflex Incorporated compare | $2.3B |
| RGEN Repligen Corporation | $805.6M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RGEN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement